Clinical Trials | December 12, 2025
Neurizon’s ALS drug regimen cleared for launch in Healey platform trial
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
The cobas Mass Spec solution Ionify reagent portfolio now covers therapeutic drug monitoring for immunosuppressants and antibiotics
The companies aim to expand treatment options for millions living with metabolic disorders
LNK01006 is designed to deliver potent, selective inhibition of TYK2-mediated cytokine signaling with central nervous system exposure
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
This approval confirms the facility's compliance with FDA quality standards and regulatory requirements
The FDA aims to make a decision by April 8, 2026
Retatrutide, tested at 9 mg and 12 mg doses alongside diet and exercise, met all primary and key secondary endpoints
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
Subscribe To Our Newsletter & Stay Updated
